Featured Story

Virginia lab zeroes in on a possible key target for male contraceptive

John Herr's lab at the University of Virginia made the cover of the scientific journal Biology of Reproduction with new work on finding a male contraceptive.

Investigators say they've designed a new-and-improved antibiotic

Francesc Rabanal, a professor in the Department of Organic Chemistry of the University of Barcelona, has spearheaded work on a new prototype compound that he says shows clear activity against both Gram-negative and Gram-positive bacteria.

Team spotlights new evidence that Parkinson's starts in the gut

Following up on what's billed as the largest epidemiological study ever done on Parkinson's disease, a group of scientists at Aarhus University in Denmark say they have determined that the neurological ailment begins in the gut and then spreads through the body by way of the vagus nerve.

Purdue group finds Achilles' heel for MERS

Researchers at Purdue University say they have identified molecules that can shut down a key enzyme needed by the Middle East respiratory syndrome, or MERS, virus.

New study will test feds' support for anti-aging drug research

Investigators will be making the trek to Washington later this month to make the case for a new study that will explore the impact that metformin has on aging. And in the process, they'll be testing regulators' attitudes about an emerging field in drug development.


From Our Sister Sites

FiercePharma Manufacturing

Consultants tell Reuters that large Indian companies are heeding the warnings from regulators and investing more in equipment and training. But some small to medium-sized companies are considering whether to pour money into their operations, retreat from high-profit but regulatory-heavy markets like the U.S. and Europe, or cash out.

FiercePharma Manufacturing

India's Dr. Reddy's Laboratories is having to recall both an epilepsy drug and a combo cardiovascular drug all made in India. One, the FDA says, is too strong while the other is not strong enough. The recalls come even as the FDA has been paying special attention to generic equivalence after testing has found evidence that some generics are not measuring up.